In 2006\, Shinya Yamanaka succeeded in identifying fo ur genes capable of reprogramming mature cells to a pluripotent state. He named these cells induced pluripotent stem (iPS) cells. Because of this br eakthrough discovery\, he won the 2012 Nobel Prize in Physiology or Medici ne. Human iPS cells have the potential to generate all types of cells in t he body and therefore provide us human-derived biomaterial for disease mod elling\, cell replacement therapy\, and drug development. To date\, human iPS cell technology has been proven to be very powerful in revealing novel pathological mechanisms of many diseases. In association with organoids\, organs-on-chips\, gene/base editing\, and “omics” methodologies\, hum an iPS cell-based technology has presented an unprecedented opportunity in biomedical research\, personalized regenerative medicine\, drug discovery \, and safety pharmacology. Additionally\, there are many ongoing and emer ging clinical trials with iPS cell-derived cell products. However\, there are also many technical challenges in translating these findings into a cl inical setting. In this vision talk\, I will summarize the progress made i n the past decade with case examples and present the current major challen ges that need to be addressed to unleash the full potential of iPS cells i n clinical settings.
Held as online seminar via Zoom:
Date:
14 July 2020
Time: 16:00
Zoom Meeting ID: 650 910 3883
Z
oom Meeting password: 01bc@yep